{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:34:04Z","timestamp":1785598444833,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochirurgie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neuchi.2026.101809","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:59:43Z","timestamp":1775753983000},"page":"101809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic management of spinal metastases: current strategies and future directions"],"prefix":"10.1016","volume":"72","author":[{"given":"H.","family":"Collin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-214X","authenticated-orcid":false,"given":"M.","family":"Cancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuchi.2026.101809_bib0005","article-title":"Incidence of bone metastases and skeletal-related events in patients with EGFR-mutated NSCLC treated with osimertinib","volume":"4","author":"Brouns","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.neuchi.2026.101809_bib0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MS9.0000000000004209","article-title":"Contemporary management strategies for spinal metastases: diagnosis, multidisciplinary approaches, and outcomes - a narrative review","volume":"88","author":"Gupta","year":"2026","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.neuchi.2026.101809_bib0015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.14245\/ns.2244290.145","article-title":"Spinal metastases and the evolving role of molecular targeted therapy, chemotherapy, and immunotherapy","volume":"19","author":"Fomchenko","year":"2022","journal-title":"Neurospine"},{"key":"10.1016\/j.neuchi.2026.101809_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241303090","article-title":"Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with EGFR-mutated non-small-cell lung cancer: a retrospective, multicenter cohort study","volume":"16","author":"Tanaka","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0025","article-title":"Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study","volume":"13","author":"Zhang","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuchi.2026.101809_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.neuchi.2026.101809_bib0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0749-2081(99)80002-3","article-title":"Metastatic epidural spinal cord compression","volume":"15","author":"Bucholtz","year":"1999","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.neuchi.2026.101809_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.suronc.2019.08.007","article-title":"Approaching spinal metastases spread profile","volume":"31","author":"Amelot","year":"2019","journal-title":"Surg Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10555-025-10262-6","article-title":"State-of-the-art of multidisciplinary approach of bone metastasis-directed therapy: review and challenging questions for preparation of a GEMO practice guidelines","volume":"44","author":"Mesny","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.neuchi.2026.101809_bib0050","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: a french prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0055","doi-asserted-by":"crossref","first-page":"e1833","DOI":"10.1002\/onco.13840","article-title":"Surgical metastasectomy in the spine: a review article","volume":"26","author":"Kato","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.neuchi.2026.101809_bib0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neuchi.2026.101809_bib0065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.neuchi.2026.101809_bib0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2022.12.028","article-title":"Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: results of the GETUG-AFU26-NIVOREN multicentre phase II study","volume":"182","author":"Velev","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neuchi.2026.101809_bib0075","article-title":"Managing bone metastases with denosumab: real-world data and critical monitoring points in breast, lung, and prostate cancers","volume":"61","author":"Oyucu Orhan","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.neuchi.2026.101809_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100738","article-title":"Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: results of the OPTIMOS study","volume":"56","author":"Confavreux","year":"2026","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21037\/tbcr-24-50","article-title":"Trastuzumab deruxtecan in patients with bone metastases from HR+\/HER2-low breast cancer: efficacy enhanced by denosumab","volume":"6","author":"Irelli","year":"2025","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.neuchi.2026.101809_bib0090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00210-010-0596-4","article-title":"Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis","volume":"383","author":"Kimachi","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.neuchi.2026.101809_bib0100","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neuchi.2026.101809_bib0110","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.neuchi.2026.101809_bib0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/medicina61020360","article-title":"A comparison of the efficacy and safety of denosumab and zoledronic acid in patients with bone metastatic breast cancer receiving CDK4\/6 inhibitor therapy","volume":"61","author":"\u00d6ner","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.neuchi.2026.101809_bib0120","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10198-018-1011-1","article-title":"Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review","volume":"20","author":"Matuoka","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.neuchi.2026.101809_bib0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.24920\/004368","article-title":"Cost-effectiveness of denosumab for treating bone metastases from solid tumors: a systematic review (2017-2023)","volume":"40","author":"Wang","year":"2025","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.neuchi.2026.101809_bib0135","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neuchi.2026.101809_bib0140","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents Cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive Breast Cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11914-015-0266-z","article-title":"Chemotherapy- and irradiation-induced bone loss in adults with solid tumors","volume":"13","author":"Wissing","year":"2015","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.neuchi.2026.101809_bib0150","first-page":"562","article-title":"Bone-targeted therapy in early breast cancer","volume":"32","author":"Jerzak","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.neuchi.2026.101809_bib0155","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jbmr.2415","article-title":"Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss","volume":"30","author":"Quach","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.neuchi.2026.101809_bib0160","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.neuchi.2026.101809_bib0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-33198-x","article-title":"Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma","volume":"16","author":"Toyoda","year":"2026","journal-title":"Sci Rep"},{"key":"10.1016\/j.neuchi.2026.101809_bib0170","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/bonekey.2015.32","article-title":"Bone specific immunity and its impact on metastasis","volume":"4","author":"Baschuk","year":"2015","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.neuchi.2026.101809_bib0175","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation","volume":"2021","author":"Liu","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.neuchi.2026.101809_bib0180","article-title":"The ineffectiveness of osimertinib in Epidermal Growth Factor Receptor (EGFR)-mutated stage IV lung adenocarcinoma with bone metastasis: a case report","volume":"16","author":"Livingston","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.neuchi.2026.101809_bib0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/10781552241275943","article-title":"Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review","volume":"31","author":"Wani","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.neuchi.2026.101809_bib0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.critrevonc.2017.09.008","article-title":"The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: an indirect comparison of randomized controlled trials","volume":"120","author":"Rizzo","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0195","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0200","article-title":"Clinical presentation and management of breast cancer with vertebral metastasis: a retrospective cohort study in Tunisia","volume":"17","author":"Samir","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.neuchi.2026.101809_bib0205","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.wneu.2022.06.060","article-title":"Surgical efficacy and prognosis of 54 cases of spinal metastases from breast cancer","volume":"165","author":"Weitao","year":"2022","journal-title":"World Neurosurg"},{"key":"10.1016\/j.neuchi.2026.101809_bib0210","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-021-00289-7","article-title":"Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups","volume":"7","author":"Johnston","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.neuchi.2026.101809_bib0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","article-title":"Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.neuchi.2026.101809_bib0220","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the Phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neuchi.2026.101809_bib0225","doi-asserted-by":"crossref","DOI":"10.1111\/crj.70107","article-title":"Comprehensive analysis of lung cancer metastasis: sites, rates, survival, and risk factors-a systematic review and meta-analysis","volume":"19","author":"Wang","year":"2025","journal-title":"Clin Respir J"},{"key":"10.1016\/j.neuchi.2026.101809_bib0230","article-title":"A scoring system for screening of patients with synchronous bone metastasis in lung cancer","volume":"105","author":"Zhao","year":"2026","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.neuchi.2026.101809_bib0235","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.3390\/cancers14143470","article-title":"Overall survival improvement in patients with epidermal growth factor receptor-mutated non-small cell lung cancer and bone metastasis treated with denosumab","volume":"14","author":"Ko","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neuchi.2026.101809_bib0240","article-title":"Efficacy of immunotherapy in patients with bone metastases from driver gene-negative non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Zhao","year":"2025","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0245","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/CCO.0000000000000167","article-title":"Immune checkpoint inhibitors in advanced nonsmall cell lung cancer","volume":"27","author":"Helissey","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.neuchi.2026.101809_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102792","article-title":"Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: a systematic literature review","volume":"129","author":"Brown","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.neuchi.2026.101809_bib0255","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Intl Journal of Cancer"},{"key":"10.1016\/j.neuchi.2026.101809_bib0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jbspin.2018.03.005","article-title":"Bone metastases from lung cancer: a paradigm for multidisciplinary onco-rheumatology management","volume":"86","author":"Confavreux","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.neuchi.2026.101809_bib0265","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4103\/jcvjs.jcvjs_147_25","article-title":"The role of multidisciplinary team meetings in the management of spinal tumors","volume":"16","author":"Pujals-Pont","year":"2025","journal-title":"J Craniovertebr Junction Spine"}],"container-title":["Neurochirurgie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028377026000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028377026000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:58:31Z","timestamp":1779454711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028377026000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0028377026000433"],"URL":"https:\/\/doi.org\/10.1016\/j.neuchi.2026.101809","relation":{},"ISSN":["0028-3770"],"issn-type":[{"value":"0028-3770","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic management of spinal metastases: current strategies and future directions","name":"articletitle","label":"Article Title"},{"value":"Neurochirurgie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuchi.2026.101809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101809"}}